Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
25.35
-1.77 (-6.53%)
At close: Aug 25, 2025, 4:00 PM
25.44
+0.09 (0.36%)
After-hours: Aug 25, 2025, 4:41 PM EDT
Moderna Revenue
Moderna had revenue of $142.00M in the quarter ending June 30, 2025, a decrease of -41.08%. This brings the company's revenue in the last twelve months to $3.08B, down -39.05% year-over-year. In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%.
Revenue (ttm)
$3.08B
Revenue Growth
-39.05%
P/S Ratio
3.40
Revenue / Employee
$530,690
Employees
5,800
Market Cap
9.86B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MRNA News
- 3 hours ago - 30 Stocks That Could Rally 30% or More - Kiplinger
- 3 days ago - Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 - Accesswire
- 4 days ago - Moderna to Present at Upcoming Conferences in September 2025 - Accesswire
- 14 days ago - FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply - Benzinga
- 19 days ago - Moderna's stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals - Market Watch
- 21 days ago - Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish - Seeking Alpha
- 23 days ago - Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent - Fast Company
- 24 days ago - Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript - Seeking Alpha